evolocumab

Evolocumab is a fully human monoclonal IgG2 antibody that targets proprotein convertase subtilisin/kexin type 9 (PCSK9). By binding to PCSK9, evolocumab inhibits its interaction with low-density lipoprotein receptors (LDLR) on hepatocytes, preventing PCSK9-mediated degradation of LDLR. This increases the number of LDLRs available to clear LDL cholesterol from the bloodstream, resulting in significant reductions in LDL-C levels. Evolocumab is primarily indicated for the treatment of hyperlipidemia and prevention of major adverse cardiovascular events in adults with established cardiovascular disease. It is administered via subcutaneous injection every two or four weeks and has demonstrated efficacy both as monotherapy and in combination with other lipid-lowering therapies[1][2][3][4]. Common side effects include nasopharyngitis, upper respiratory tract infection, back pain, injection site reactions, and rarely allergic reactions[2][5]. Developed by Amgen, it was first approved for medical use in 2015[1][3].

Brand names

Repatha瑞百安

Other names

伊诺尤单抗依洛尤单抗